PCSK9 as a therapeutic target of dyslipidemia
Author:
Publisher
Informa Healthcare
Subject
Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/14728220802600715
Reference93 articles.
1. JTT-705: is there still future for a CETP inhibitor after torcetrapib?
2. Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis
3. CP-346086
4. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor,in vivoandin vitro
Cited by 113 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. PCSK9 inhibitors as safer therapeutics for atherosclerotic cardiovascular disease (ASCVD): Pharmacophore design and molecular dynamics analysis;Journal of Cellular Biochemistry;2024-05-15
2. Triticum aestivum Octacosanol, a Potential Inhibitor of PCSK9 in Fat Diet–Induced Hypercholesteromia;Revista Brasileira de Farmacognosia;2024-04-23
3. Discovery of (2‐(4‐Substituted phenyl)quinolin‐4‐yl)(4‐isopropylpiperazin‐1‐yl)methanone Derivatives as Potent Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors;ChemMedChem;2023-12-13
4. Inhibición de PCSK9: una nueva alternativa para reducir el colesterol y prevenir la enfermedad cardiovascular aterosclerosa;Salud, Ciencia y Tecnología;2023-11-13
5. Lipoprotein(a) in patients with breast cancer after chemotherapy: exploring potential strategies for cardioprotection;Lipids in Health and Disease;2023-09-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3